Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (241-250 of 320) with videos related to

Pageof 32
Sort By:
JAMA Network Open|November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical TrialsPasi A Jänne, David Planchard, Koichi Goto, et al.
Cell Reports|April 2, 2014
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3Chong Sun, Sebastijan Hobor, Andrea Bertotti, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
The Lancet. Oncology|April 16, 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialDavid Planchard, Tae Min Kim, Julien Mazieres, et al.
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and ImmunotherapyConor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomographyAstrid A M van der Veldt, Mark Lubberink, Henri N Greuter, et al.
Frontiers in Oncology|March 19, 2021
Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving ImmunotherapyStefano Trebeschi, Zuhir Bodalal, Thierry N Boellaard, et al.
Cancer Cell|November 4, 2015
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer DiagnosticsMyron G Best, Nik Sol, Irsan Kooi, et al.
Journal of Clinical Pathology|August 7, 2016
DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 yearsA Jasmijn Hubers, Daniëlle A M Heideman, Sylvia Duin, et al.
Pageof 32

Showing results (241-250 of 320) with videos related to

Sort By:
Pageof 32
JAMA Network Open|November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical TrialsPasi A Jänne, David Planchard, Koichi Goto, et al.
Cell Reports|April 2, 2014
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3Chong Sun, Sebastijan Hobor, Andrea Bertotti, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
The Lancet. Oncology|April 16, 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialDavid Planchard, Tae Min Kim, Julien Mazieres, et al.
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and ImmunotherapyConor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomographyAstrid A M van der Veldt, Mark Lubberink, Henri N Greuter, et al.
Frontiers in Oncology|March 19, 2021
Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving ImmunotherapyStefano Trebeschi, Zuhir Bodalal, Thierry N Boellaard, et al.
Cancer Cell|November 4, 2015
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer DiagnosticsMyron G Best, Nik Sol, Irsan Kooi, et al.
Journal of Clinical Pathology|August 7, 2016
DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 yearsA Jasmijn Hubers, Daniëlle A M Heideman, Sylvia Duin, et al.
Pageof 32